Alpha Tau reports Q3 2026 financial results
It posts a $98.9 million nine-month net loss and holds $99.8 million in cash, while reporting REGAIN glioblastoma responses and completing IMPACT enrollment.
See the latest news and media coverage for Alpha Tau. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage oncology company developing intratumoral alpha-emitting radiotherapeutics
alphatau.comLast updated
In short: Alpha Tau reported positive interim REGAIN results, with all six evaluable patients responding
It posts a $98.9 million nine-month net loss and holds $99.8 million in cash, while reporting REGAIN glioblastoma responses and completing IMPACT enrollment.
All eight treated patients remain alive with median overall survival not reached, and all six evaluable patients achieved an objective response.
CEO Uzi Sofer reflects on the company's 20-year scientific journey to develop Alpha DaRT cancer treatment and thanks stakeholders.
The company reported a $68.8 million net loss, $104.8 million cash balance, and Tolmar collaboration for prostate cancer, with multiple clinical milestones.
New interim results from the U.S. REGAIN recurrent glioblastoma trial presented at the SNO 2026 Annual Meeting: all eight treated patients alive, with median overall...
Alpha Tau Medical reports a 100% objective response rate and strong safety in interim U.S. REGAIN...
Detailed price information for Alpha Tau Medical Ltd Cl A (DRTS-Q) from The Globe and Mail including charting and trades.
JERUSALEM, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation...
Track Alpha Tau and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.